Zimmer Biomet   Report issue

For profit Phase 1 Phase 4
Founded: Warsaw IN United States (1927)
Status: No NME R&D (1927)

Organization Overview

First Clinical Trial
2007
NCT00757289
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Zimmer Biomet | Zimmer Medical Devices (Shanghai) Co., Ltd.

Active Ingredients

Drugs in Phase 4 Trials (3)

Key: Zimmer Biomet (1) Acquired (2)

bone mineral matrix (1 trial)

platelet-rich plasma (5 trials)

red blood cells (1 trial)

Drugs in Phase 1 Trials (1)

Key: Zimmer Biomet (0) Acquired (1)

autologous protein solution (1 trial)

Drugs in Other Trials (3)

Key: Zimmer Biomet (0) Acquired (3)

atorvastatin (lipitor) (1 trial)

desogestrel (Mercilon) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fasciitis (Phase 4)

Fasciitis, Plantar (Phase 4)

Intervertebral Disc Degeneration (Phase 4)

Osteoarthritis (Phase 1)

Osteoarthritis, Knee (Phase 1)

Tendinopathy (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 7